UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...

(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

Opuviz, which references Regeneron Pharmacueticals’ vision loss inhibitor Eylea, treats wet age-related macular degeneration, ...

Stephen Abreu has been appointed by the Board as Executive Director. He will lead the organization's overall strategy and ...

Medline today announced that it has expanded its medical surgical prime vendor agreement with Northern California-based ...

CVS Health® today announced that Dr. Sreekanth Chaguturu will be President, Health Care Delivery, in addition to his current role as Executive Vice President and Chief Medical Officer of CVS Health.

Biogen had planned to sell the drug for $56,000 for a year ... When there is so much money on the table, people will cheat, just as they are willing to break the law to sell fentanyl and other illegal ...

“We now need Biogen, the pharmaceutical company that manufactures Tofersen, to come back to the table and get the application ...

Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...

Asian equities are poised to track Wall Street stocks higher as Treasuries halted a selloff that drove 10-year yields near ...